Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-3164 in Relapsed/Refractory NHL
NCT05979857Phase 1Not yet recruiting
- Sponsor
- Salarius Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Aug 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment), Molecular Glues
01
Overview
Phase 1, randomised, open-label trial of SP-3164 in Non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Salarius Pharmaceuticals. Primary endpoints: Characterize the Safety of SP-3164 at 4 months, Assess Dose Limiting Toxicities of SP-3164 at 6 months and 3 more. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
SP-3164
03
Conditions
Non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05979857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979857.